Pamidronic acid

Generic Name: Pamidronic acid

Brand Names: Pamisol

Drug Type: Small Molecule

Chemical Formula: C_₃H_₁₁NO_₇P_₂

CAS Number: 40391-99-9

Unique Ingredient Identifier: OYY3447OMC

Background: Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to neridronic acid and alendronic acid. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as ibandronic acid, zoledronic acid, minodronic acid, and risedronic acid are ...

Indication: Pamidronate is indicated to treat moderate to severe hypercalcemia of malignancy, moderate to severe Paget's disease of bone, osteolytic bone metastases of breast cancer, and osteolytic lesions of multiple myeloma.

Associated Conditions: Hypercalcemia of Malignancy, Osteolytic lesion, Paget’s Disease, Osteolytic Bone metastases

Associated Therapies: -

Clinical Trials

Efficacy of Pamidronate in the Treatment of Bone Loss Associated With Liver Transplant

Phase 4

Completed

Conditions: Bone Disease, Metabolic

Interventions: Drug: Placebo
Drug: Disodium pamidronate

First Posted Date: 2008-04-14

Last Posted Date: 2008-04-14

Lead Sponsor: Hospital Clinic of Barcelona

Target Recruit Count: 79

Registration Number: NCT00657852

Locations: 🇪🇸
Hospital Clinic i Provincial of Barcelona, Barcelona, Spain

Prevention of Post Operative Bone Loss in Children

Not Applicable

Completed

Conditions: Osteoporosis
Spina Bifida
Cerebral Palsy
Osteogenesis Imperfecta
Osteopenia

Interventions: Other: saline
Drug: pamidronate

First Posted Date: 2008-04-10

Last Posted Date: 2023-08-22

Lead Sponsor: University of New Mexico

Target Recruit Count: 24

Registration Number: NCT00655681

Locations: 🇺🇸
University of New Mexico Carrie Tingley Hospital, Albuquerque, New Mexico, United States

Effect of Local Pamidronate in Preventing Bone Loss After Total Hip Arthroplasty

Phase 1

Not yet recruiting

Conditions: Mineral Density
Arthroplasty

First Posted Date: 2007-10-23

Last Posted Date: 2024-04-15

Lead Sponsor: General and Teaching Hospital Celje

Target Recruit Count: 40

Registration Number: NCT00548288

Locations: 🇸🇮
Department for Orthopaedic Surgery and Sports Trauma, Celje Teaching Hospital, Celje, Slovenia

Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Pain

Interventions: Drug: Pamidronate
Drug: Zoledronic acid
Radiation: Sm 153 lexidronam

First Posted Date: 2007-06-05

Last Posted Date: 2018-08-14

Lead Sponsor: Mayo Clinic

Target Recruit Count: 39

Registration Number: NCT00482378

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month

Phase 3

Completed

Conditions: Multiple Myeloma

First Posted Date: 2006-09-15

Last Posted Date: 2007-01-04

Lead Sponsor: Nordic Myeloma Study Group

Target Recruit Count: 500

Registration Number: NCT00376883

Locations: 🇩🇰
Department of Haematology B, Aalborg Hospital, University of Aarhus, Aalborg, Denmark
🇩🇰
Department of Hematology L, Rigshospitalet, København Ø, Denmark
🇳🇴
Hematologisk seksjon, St.Olav Hospital, Trondheim, Norway

and more 11 locations

Pamidronate, Vitamin D, and Calcium for the Bone Disease of Kidney and Heart Transplantation

Not Applicable

Completed

Conditions: Transplant Bone Disease

Interventions: Drug: Pamidronate
Drug: vitamin D
Drug: Calcium Carbonate

First Posted Date: 2006-03-14

Last Posted Date: 2018-08-29

Lead Sponsor: Providence Health & Services

Target Recruit Count: 43

Registration Number: NCT00302627

Locations: 🇺🇸
Providence Medical Research Center, Spokane, Washington, United States

Bisphosphonate Therapy for Osteogenesis Imperfecta

Phase 4

Completed

Conditions: Osteogenesis Imperfecta
Osteoporosis
Paget Disease of Bone

Interventions: Drug: Pamidronate
Drug: Alendronate

First Posted Date: 2005-09-12

Last Posted Date: 2017-06-14

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 18

Registration Number: NCT00159419

Pamidronate Administration in Breast Cancer Patients With Bone Metastases

Phase 4

Completed

Conditions: Breast Cancer
Neoplasm Metastasis

Interventions: Drug: Pamidronate

First Posted Date: 2005-08-09

Last Posted Date: 2023-03-28

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 152

Registration Number: NCT00128297

Locations: 🇪🇸
Spanish Breast Cancer Research Group (GEICAM), San Sebastián de los Reyes, Madrid, Spain

Osteopenia and Renal Osteodystrophy: Evaluation and Management

Phase 4

Completed

Conditions: Osteopenia
Renal Osteodystrophy

First Posted Date: 2005-04-15

Last Posted Date: 2009-01-21

Lead Sponsor: US Department of Veterans Affairs

Registration Number: NCT00108394

Locations: 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States

A Pilot Trial of Intravenous (IV) Pamidronate for Low Back Pain

Phase 1

Conditions: Low Back Pain

Interventions: Drug: pamidronate

First Posted Date: 2005-01-14

Last Posted Date: 2010-01-07

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 44

Registration Number: NCT00101790

Locations: 🇺🇸
The Mount Sinai Medical Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy